리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 06월
페이지 정보:영문 380 Pages
라이선스 & 가격 (부가세 별도)
한글목차
우울증 치료제 세계 시장은 2030년까지 201억 달러에 이를 전망
2024년에 179억 달러로 추정되는 우울증 치료제 세계 시장은 분석 기간인 2024-2030년 CAGR 1.9%로 성장하여 2030년에는 201억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 비정형 항정신병제는 CAGR 1.8%를 나타내고, 분석 기간 종료시에는 45억 달러에 이를 것으로 예측됩니다. 세로토닌-노르에피네프린 재흡수 억제제 부문의 성장률은 분석 기간중 CAGR 1.3%로 추정됩니다.
미국 시장은 49억 달러로 추정, 중국은 CAGR 3.6%로 성장 예측
미국의 우울증 치료제 시장은 2024년에는 49억 달러에 이를 것으로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 37억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 3.6%로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 0.8%와 1.6%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 1.1%로 추정됩니다.
세계의 우울증 치료제 시장 - 주요 동향과 촉진요인 정리
전 세계적으로 우울증 치료제에 대한 수요가 계속 증가하는 이유는 무엇일까?
우울증은 여전히 전 세계적으로 가장 널리 퍼져있는 정신질환 중 하나이며, 약리학적 치료에 대한 지속적인 수요를 주도하고 있습니다. 주요우울장애(MDD), 양극성 우울증, 조울증, 기분부전증, 계절성 정서장애는 전 세계 정신질환 부담의 상당 부분을 차지합니다. 진단 사례의 지속적인 증가는 사회적 인식 증가, 편견의 감소, 정신과 의료 접근성 향상, 항우울제 처방의 지속적인 증가에 기인한 것으로 분석됩니다. 또한, 경제적 스트레스, 분쟁, 팬데믹으로 인한 고립 등 최근 전 세계적으로 발생한 사건들은 효과적이고 확장 가능한 정신 건강 대책의 필요성을 더욱 높이고 있습니다.
항우울제는 신경 화학적 불균형을 안정시키고 지속적인 슬픔, 의욕 상실, 자살 충동과 같은 증상을 완화하는 데 중요한 역할을 합니다. 항우울제는 만성 통증, 불안, 수면장애 등 적응증 외 사용에도 자주 처방되어 그 치료적 유용성이 확대되고 있습니다. 의료 시스템이 정신건강을 우선순위에 두고 1차의료 모델에 통합함에 따라 항우울제 치료는 최전방 치료 옵션이 되고 있으며, 제네릭과 브랜드 의약품의 성장을 주도하고 있습니다.
임상적 필요를 충족시키기 위해 약물의 유형과 새로운 작용기전은 어떻게 진화하고 있는가?
우울증 치료제 시장은 선택적 세로토닌 재흡수 억제제(SSRI), 세로토닌 노르에피네프린 재흡수 억제제(SNRI), 삼환계 항우울제(TCA), 모노아민 산화효소 억제제(MAOI) 등 몇 가지 확립된 계열로 구성되어 있습니다. 우수한 안전성 프로파일, 사용 편의성, 광범위한 적용 가능성으로 인해 처방의 대부분을 차지하고 있습니다. 그러나 작용 발현 지연, 부분적 반응, 체중 증가 및 성기능 장애와 같은 부작용 등의 한계로 인해 대체 치료의 필요성이 강조되고 있습니다.
이에 따라 새로운 작용기전을 가진 약물이 등장하고 있으며, NMDA 수용체 길항제와 같은 글루타메이트 작용성 경로를 표적으로 하는 비정형 항우울제는 빠른 효과로 주목을 받고 있습니다. 예를 들어, 에스케타민 비강 점안제는 치료 저항성 우울증의 증상을 빠르게 완화합니다. 한편, 멜라토닌 수용체 및 기타 신경 펩타이드를 조절하는 약물은 우울증에 수반되는 일주기 리듬 장애에 대처하기 위해 연구되고 있습니다. 이러한 기술 혁신은 모노아민 표적 치료에서 신경회로 조절 치료로의 큰 전환을 의미하며, 보다 개인화되고 즉각적인 치료 옵션을 제공할 것으로 기대됩니다.
시장 경쟁에 영향을 미치는 규제 및 상업적 동향은?
주요 항우울제의 특허 만료는 특히 성숙된 시장에서 제네릭 의약품의 견고한 제네릭 의약품 상황을 만들어 가격 경쟁을 심화시키고, 구매하기 쉬운 가격으로 개선하고 있습니다. 그러나 이는 또한 치료 저항성 우울증, 청소년 및 소아 우울증, 불안 및 약물 남용을 동반한 우울증과 같은 미충족 수요를 타겟으로 하는 차별화 된 치료에 대한 제약사의 투자를 촉진하고 있습니다. 치료가 어려운 집단에서 임상적 가치를 입증한 혁신적 의약품은 규제 당국의 신속한 승인, 희귀질환 치료제 지정, 획기적 치료제로서의 지위를 인정받고 있습니다.
제약사들은 브랜드 독점권을 유지하기 위해 서방형 제제, 병용요법, 새로운 전달 시스템 등 라이프사이클 관리 전략을 활용하고 있습니다. 생명공학 기업과 정신 건강 관련 스타트업과의 제휴는 디지털 바이오마커와 AI 기반 환자 모니터링을 통한 의약품 개발을 촉진하고 있습니다. 이러한 도구는 보다 반응성이 높은 하위 그룹을 식별하고, 순응도를 모니터링하고, 실시간으로 결과를 측정하는 데 도움이 되고 있으며, 우울증 치료제 개발은 점점 더 데이터 중심적이고 환자 중심적으로 변화하고 있습니다.
우울증 치료제 시장의 성장을 가속하는 주요 요인은?
항우울제 시장의 성장은 전 연령층에 걸친 정신적 부담 증가, 진단율 증가, 1차 선택 치료로서 약리학적 개입으로의 지속적인 전환 등 여러 요인에 의해 이루어지고 있습니다. 정신 건강 서비스가 1차 진료 및 원격 의료 플랫폼에 통합되면서 항우울제의 접근성이 향상되고, 정신 건강 질환에 대한 보험 적용 범위가 확대되면서 비용과 관련된 치료 장벽이 제거되고 있습니다. 이는 인프라가 개선되고 정신과 의료에 대한 문화적 편견이 점차 사라지고 있는 신흥 경제국에서 특히 중요합니다.
신경생물학 분야의 과학적 발전으로 인해 보다 즉각적인 표적 치료법이 발견되고 있으며, 이는 조기에 증상을 개선하고자 하는 의사와 환자 모두에게 매력적으로 다가오고 있습니다. 또한, 맞춤 치료 경로에 대한 관심이 높아지면서 다양한 약물 계열과 약물 전달 시스템에 대한 수요가 증가하고 있습니다. 공중보건 시스템이 우울증에 대한 조기 개입과 지속적인 치료를 우선시하는 가운데, 제약 혁신, 디지털 치료 통합, 치료 가이드라인의 확대는 선진국과 신흥국 모두에서 시장 확대의 원동력이 될 것으로 보입니다.
Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 큐레이트된 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트(UAE)
기타 중동
아프리카
제4장 경쟁
LSH
영문 목차
영문목차
Global Depression Drugs Market to Reach US$20.1 Billion by 2030
The global market for Depression Drugs estimated at US$17.9 Billion in the year 2024, is expected to reach US$20.1 Billion by 2030, growing at a CAGR of 1.9% over the analysis period 2024-2030. Atypical Antipsychotics, one of the segments analyzed in the report, is expected to record a 1.8% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Serotonin-Norepinephrine Reuptake Inhibitors segment is estimated at 1.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$4.9 Billion While China is Forecast to Grow at 3.6% CAGR
The Depression Drugs market in the U.S. is estimated at US$4.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.7 Billion by the year 2030 trailing a CAGR of 3.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.
Global Depression Drugs Market - Key Trends & Drivers Summarized
Why Does the Demand for Depression Drugs Continue to Escalate Worldwide?
Depression remains one of the most prevalent and debilitating mental health disorders globally, driving sustained demand for pharmacological treatments. Major depressive disorder (MDD), bipolar depression, dysthymia, and seasonal affective disorder collectively account for a substantial share of the global mental illness burden. The ongoing rise in diagnosed cases-partly fueled by growing public awareness, reduced stigma, and improved access to psychiatric care-has led to a consistent increase in the prescription of antidepressant medications. Additionally, recent global events, including economic stress, conflict, and pandemic-related isolation, have heightened the need for effective, scalable mental health solutions.
Depression drugs serve a critical role in stabilizing neurochemical imbalances and alleviating symptoms such as persistent sadness, lack of motivation, and suicidal ideation. Antidepressants are also frequently prescribed for off-label uses such as chronic pain, anxiety, and sleep disorders, expanding their therapeutic utility. As healthcare systems prioritize mental health and integrate it into primary care models, antidepressant therapy is becoming a frontline treatment option, driving growth in both generic and branded drug segments.
How Are Drug Classes and Novel Mechanisms of Action Evolving to Meet Clinical Needs?
The depression drug market comprises several well-established classes, including Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), and Monoamine Oxidase Inhibitors (MAOIs). SSRIs and SNRIs dominate prescriptions due to their favorable safety profiles, ease of use, and broad applicability. However, limitations such as delayed onset of action, partial response, and side effects including weight gain and sexual dysfunction have underscored the need for alternative treatments.
This has led to the emergence of newer agents with novel mechanisms of action. Atypical antidepressants targeting glutamatergic pathways, such as NMDA receptor antagonists, are gaining attention for their rapid-acting effects. Esketamine nasal spray, for example, offers fast symptom relief in treatment-resistant depression. Meanwhile, drugs modulating melatonin receptors and other neuropeptides are under investigation to address circadian rhythm disruptions associated with depressive states. These innovations mark a significant shift from monoamine-targeting therapies to neurocircuitry modulation, promising more personalized and fast-acting treatment options.
What Are the Regulatory and Commercial Trends Influencing Market Competition?
Patent expiries of major antidepressants have created a robust generic drug landscape, particularly in mature markets, intensifying price competition and improving affordability. However, this has also pushed pharmaceutical companies to invest in differentiated therapies targeting unmet needs, such as treatment-resistant depression, adolescent and pediatric depression, and depression with co-morbid anxiety or substance abuse. Fast-track regulatory approvals, orphan designations, and breakthrough therapy statuses are being granted to innovative drugs that demonstrate clinical value in hard-to-treat populations.
Pharma companies are also leveraging lifecycle management strategies, including extended-release formulations, combination therapies, and novel delivery systems to sustain brand exclusivity. Partnerships between biotech firms and mental health startups are facilitating drug development using digital biomarkers and AI-based patient monitoring. These tools are helping identify more responsive subgroups, monitor adherence, and measure real-time outcomes, making depression drug development increasingly data-driven and patient-centric.
What Are the Primary Forces Propelling Growth in the Depression Drugs Market?
The growth in the depression drugs market is driven by several factors, including rising mental health burden across age groups, expanding diagnosis rates, and the continued shift toward pharmacological intervention as a first-line treatment. The integration of mental health services into primary and telehealth care platforms is making antidepressants more accessible, while broader insurance coverage for mental health conditions is removing cost-related treatment barriers. This is especially critical in emerging economies where infrastructure is improving and cultural stigma around psychiatric care is gradually diminishing.
Scientific advancements in neurobiology are enabling the discovery of faster-acting and more targeted therapies, appealing to both physicians and patients seeking quicker symptom resolution. Additionally, the growing focus on individualized treatment pathways is fostering demand for diversified drug classes and delivery systems. As public health systems prioritize early intervention and continuity of care for depression, pharmaceutical innovation, digital therapeutics integration, and expanded treatment guidelines will continue to drive market expansion in both developed and emerging regions.
SCOPE OF STUDY:
The report analyzes the Depression Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Class (Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Other Drug Classes); Drug Type (Generic Drugs, Branded Drugs); Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Other Disorders)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 32 Featured) -
AbbVie Inc.
Alkermes plc
AstraZeneca plc
Bausch Health Companies Inc.
Bristol Myers Squibb Company
Cipla Limited
Dr. Reddy's Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
H. Lundbeck A/S
Johnson & Johnson
Lupin Limited
Luye Pharma Group Ltd.
Novartis International AG
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Ltd.
Teva Pharmaceutical Industries Ltd.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Depression Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Global Prevalence of Major Depressive Disorder Propels Long-Term Demand for Antidepressant Therapies
Increased Mental Health Awareness and Screening Strengthens Early Diagnosis and Treatment Rates
Expansion of Telepsychiatry and Digital Prescribing Channels Throws the Spotlight on Medication Access
Growth in SSRI and SNRI Drug Classes Continues to Dominate First-Line Depression Management
Innovation in Fast-Acting Antidepressants Fuels Market Differentiation
Regulatory Approvals for Novel Mechanisms Expand the Treatment Toolbox
Rising Demand for Personalized Psychiatry Supports Pharmacogenomic-Guided Drug Selection
Shift Toward Combination Therapy and Adjunctive Treatments Enhances Use of Atypical Antidepressants
Increased Focus on Adherence, Side Effects, and Tolerability Drives Extended-Release Formulation R&D
Integration of Digital Therapeutics With Drug Therapy Enhances Monitoring and Outcome Tracking
Mental Health Coverage Expansion in Insurance Policies Supports Prescription Uptake
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Depression Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Depression Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Depression Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Depression Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Atypical Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Atypical Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Atypical Antipsychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Selective Serotonin Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Selective Serotonin Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Selective Serotonin Reuptake Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Central Nervous System Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Central Nervous System Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Central Nervous System Stimulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Tricyclic Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Tricyclic Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Tricyclic Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Monoamine Oxidase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Monoamine Oxidase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Monoamine Oxidase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 25: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Major Depressive Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Major Depressive Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 28: World 16-Year Perspective for Major Depressive Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Obsessive-Compulsive Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 31: World 16-Year Perspective for Obsessive-Compulsive Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Generalized Anxiety Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Generalized Anxiety Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 34: World 16-Year Perspective for Generalized Anxiety Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Panic Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Panic Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 37: World 16-Year Perspective for Panic Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Other Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 39: World Historic Review for Other Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 40: World 16-Year Perspective for Other Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 42: World Historic Review for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 43: World 16-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 44: World Recent Past, Current & Future Analysis for Branded Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 45: World Historic Review for Branded Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 46: World 16-Year Perspective for Branded Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 47: USA Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: USA Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 49: USA 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: USA Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 52: USA 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 53: USA Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: USA Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 55: USA 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
CANADA
TABLE 56: Canada Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 58: Canada 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 59: Canada Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 61: Canada 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 62: Canada Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Canada Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 64: Canada 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
JAPAN
Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 65: Japan Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Japan Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 67: Japan 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 68: Japan Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 70: Japan 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 71: Japan Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Japan Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 73: Japan 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
CHINA
Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 74: China Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: China Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 76: China 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 77: China Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: China Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 79: China 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 80: China Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: China Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 82: China 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
EUROPE
Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 83: Europe Recent Past, Current & Future Analysis for Depression Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Depression Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 85: Europe 16-Year Perspective for Depression Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 86: Europe Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Europe Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 88: Europe 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 89: Europe Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Europe Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 91: Europe 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 92: Europe Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Europe Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 94: Europe 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
FRANCE
Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 95: France Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: France Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 97: France 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 98: France Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: France Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 100: France 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 101: France Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: France Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 103: France 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
GERMANY
Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 104: Germany Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Germany Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 106: Germany 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 107: Germany Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Germany Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 109: Germany 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 110: Germany Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: Germany Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 112: Germany 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
ITALY
TABLE 113: Italy Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Italy Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 115: Italy 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 116: Italy Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Italy Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 118: Italy 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 119: Italy Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: Italy Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 121: Italy 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
UNITED KINGDOM
Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 122: UK Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: UK Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 124: UK 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 125: UK Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: UK Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 127: UK 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 128: UK Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: UK Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 130: UK 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
SPAIN
TABLE 131: Spain Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Spain Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 133: Spain 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 134: Spain Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Spain Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 136: Spain 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 137: Spain Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Spain Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 139: Spain 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
RUSSIA
TABLE 140: Russia Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Russia Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 142: Russia 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 143: Russia Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Russia Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 145: Russia 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 146: Russia Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Russia Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 148: Russia 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Rest of Europe Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 151: Rest of Europe 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Rest of Europe Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 154: Rest of Europe 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Rest of Europe Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 157: Rest of Europe 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Depression Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 160: Asia-Pacific 16-Year Perspective for Depression Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Asia-Pacific Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 163: Asia-Pacific 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Asia-Pacific Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 166: Asia-Pacific 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: Asia-Pacific Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 169: Asia-Pacific 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
AUSTRALIA
Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 170: Australia Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: Australia Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 172: Australia 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 173: Australia Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: Australia Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 175: Australia 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 176: Australia Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: Australia Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 178: Australia 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
INDIA
Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 179: India Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: India Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 181: India 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 182: India Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: India Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 184: India 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 185: India Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: India Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 187: India 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 188: South Korea Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: South Korea Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 190: South Korea 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 191: South Korea Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: South Korea Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 193: South Korea 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 194: South Korea Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: South Korea Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 196: South Korea 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: Rest of Asia-Pacific Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Rest of Asia-Pacific Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Rest of Asia-Pacific Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
LATIN AMERICA
Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 206: Latin America Recent Past, Current & Future Analysis for Depression Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for Depression Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 208: Latin America 16-Year Perspective for Depression Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 209: Latin America Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Latin America Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 211: Latin America 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 212: Latin America Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Latin America Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 214: Latin America 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 215: Latin America Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: Latin America Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 217: Latin America 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 218: Argentina Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: Argentina Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 220: Argentina 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 221: Argentina Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: Argentina Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 223: Argentina 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 224: Argentina Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: Argentina Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 226: Argentina 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
BRAZIL
TABLE 227: Brazil Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: Brazil Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 229: Brazil 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 230: Brazil Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: Brazil Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 232: Brazil 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 233: Brazil Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: Brazil Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 235: Brazil 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
MEXICO
TABLE 236: Mexico Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 237: Mexico Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 238: Mexico 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 239: Mexico Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 240: Mexico Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 241: Mexico 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 242: Mexico Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 243: Mexico Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 244: Mexico 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 246: Rest of Latin America Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 247: Rest of Latin America 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 249: Rest of Latin America Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 250: Rest of Latin America 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 252: Rest of Latin America Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 253: Rest of Latin America 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
MIDDLE EAST
Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 254: Middle East Recent Past, Current & Future Analysis for Depression Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for Depression Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 256: Middle East 16-Year Perspective for Depression Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 257: Middle East Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 258: Middle East Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 259: Middle East 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 260: Middle East Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: Middle East Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 262: Middle East 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 263: Middle East Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Middle East Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 265: Middle East 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
IRAN
TABLE 266: Iran Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Iran Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 268: Iran 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 269: Iran Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Iran Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 271: Iran 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 272: Iran Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Iran Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 274: Iran 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
ISRAEL
TABLE 275: Israel Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 276: Israel Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 277: Israel 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 278: Israel Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: Israel Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 280: Israel 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 281: Israel Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: Israel Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 283: Israel 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: Saudi Arabia Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 286: Saudi Arabia 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: Saudi Arabia Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 289: Saudi Arabia 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: Saudi Arabia Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 292: Saudi Arabia 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 293: UAE Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: UAE Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 295: UAE 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 296: UAE Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: UAE Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 298: UAE 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 299: UAE Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: UAE Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 301: UAE 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 303: Rest of Middle East Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 304: Rest of Middle East 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 306: Rest of Middle East Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 307: Rest of Middle East 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 309: Rest of Middle East Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 310: Rest of Middle East 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030
AFRICA
Depression Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 311: Africa Recent Past, Current & Future Analysis for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 312: Africa Historic Review for Depression Drugs by Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 313: Africa 16-Year Perspective for Depression Drugs by Drug Class - Percentage Breakdown of Value Sales for Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Central Nervous System Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
TABLE 314: Africa Recent Past, Current & Future Analysis for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 315: Africa Historic Review for Depression Drugs by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 316: Africa 16-Year Perspective for Depression Drugs by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2014, 2025 & 2030
TABLE 317: Africa Recent Past, Current & Future Analysis for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 318: Africa Historic Review for Depression Drugs by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 319: Africa 16-Year Perspective for Depression Drugs by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2025 & 2030